Sacubitril/Valsartan in Anthracycline-Treated Patients: A Systematic Review and Meta-Analysis of Available Evidence [0.03%]
蒽环类药物治疗患者使用沙库必曲/缬沙坦：现有证据的系统评价和荟萃分析
Luigi Spadafora,Massimiliano Camilli
Luigi Spadafora
Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework: JACC Cardio-Oncology Primer [0.03%]
免疫检查点抑制剂性心肌炎重新挑战：证据及实操框架：JACC心脏肿瘤学简介
Joe-Elie Salem,Stephane Ederhy,Meiying Zhang et al.
Joe-Elie Salem et al.
Correction [0.03%]
改正
Published Erratum
JACC. CardioOncology. 2026 Jun;8(3):335-337. DOI:10.1016/j.jaccao.2026.05.001 2026
Bonnie Ky
Bonnie Ky
Exploring Overlooked Mediators Linking Myocardial Infarction to Hematologic Malignancies [0.03%]
探索心肌梗死与血液系统恶性肿瘤之间 overlooked 的中介因素
Parth Aphale,Shashank Dokania,Himanshu Shekhar
Parth Aphale
REPLY: Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction [0.03%]
对癌症治疗相关心脏功能障碍的血管生物标志物指导的风险分层进行修正：回复文章
Priya Mistry,Dakota Gustafson,Paaladinesh Thavendiranathan et al.
Priya Mistry et al.
REPLY: Reframing Mechanistic and Clinical Paradigms of Osimertinib-Associated Cardiotoxicity [0.03%]
奥希替尼相关心脏毒性的机制和临床范式的再思考回复信
Yuta Tanaka,Yasuhisa Tatebe,Hirofumi Hamano et al.
Yuta Tanaka et al.
Reframing Mechanistic and Clinical Paradigms of Osimertinib-Associated Cardiotoxicity [0.03%]
奥希替尼相关心脏毒性的机制和临床范式的再思考
Defeng Zhao,Danni Li
Defeng Zhao
Treatment and Outcomes in Myocardial Infarction and Cancer-A German Real-Life Analysis [0.03%]
德国现实生活中心肌梗死合并癌症的治疗及预后分析
Stefanos T Papageorgiou,Jannik Feld,Christiane Engelbertz et al.
Stefanos T Papageorgiou et al.